keyword
https://read.qxmd.com/read/38101433/atezolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-untreated-locally-advanced-or-metastatic-urothelial-carcinoma-imvigor130-final-overall-survival-analysis-results-from-a-randomised-controlled-phase-3-study
#1
RANDOMIZED CONTROLLED TRIAL
Enrique Grande, José Á Arranz, Maria De Santis, Aristotelis Bamias, Eiji Kikuchi, Xavier Garcia Del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Fabio A Schutz, Javier Puente, Jian-Ri Li, Peter H O'Donnell, Arash Rezazadeh Kalebasty, Dingwei Ye, Sanjeev Mariathasan, FabioIa Bene-Tchaleu, Sandrine Bernhard, Chooi Lee, Ian D Davis, Matthew D Galsky
BACKGROUND: IMvigor130 demonstrated statistically significant investigator-assessed progression-free survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) versus placebo plus platinum-based chemotherapy (group C) in patients with locally advanced or metastatic urothelial carcinoma. Overall survival was not improved in interim analyses. Here we report the final overall analysis for group A versus group C. METHODS: In this global, partially blinded, randomised, controlled, phase 3 study, patients (aged ≥18 years) with previously untreated locally advanced or metastatic urothelial cancer and who had an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled at 221 hospitals and oncology centres in 35 countries...
January 2024: Lancet Oncology
https://read.qxmd.com/read/38046378/multicenter-retrospective-study-to-evaluate-necitumumab-plus-cisplatin-and-gemcitabine-after-immune-checkpoint-inhibitors-in-advanced-squamous-cell-lung-cancer-in-japan-the-ninja-study
#2
JOURNAL ARTICLE
Yasunori Murata, Shigeru Tanzawa, Toshihiro Misumi, Hiroshige Yoshioka, Eisaku Miyauchi, Kiichiro Ninomiya, Masafumi Takeshita, Kensaku Ito, Tatsuro Okamoto, Shunichi Sugawara, Yosuke Kawashima, Kazuki Hashimoto, Masahide Mori, Akihiko Miyanaga, Anna Hayashi, Hisashi Tanaka, Ryoichi Honda, Masafumi Nojiri, Yuki Sato, Akito Hata, Ken Masuda, Toshiyuki Kozuki, Takahisa Kawamura, Takuji Suzuki, Teppei Yamaguchi, Kazuhiro Asada, Satoshi Tetsumoto, Hiroshi Tanaka, Satoshi Watanabe, Yukihiro Umeda, Kakuhiro Yamaguchi, Shoichi Kuyama, Kosuke Tsuruno, Yuki Misumi, Hiroshi Kuraishi, Ken Yoshihara, Akira Nakao, Akihito Kubo, Toshihiko Yokoyama, Kana Watanabe, Nobuhiko Seki
INTRODUCTION: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previously treated with immune checkpoint inhibitors (ICIs) remain unknown. METHODS: This multicenter, retrospective, cohort study assessed the efficacy and tolerability of GCN initiated between November 1, 2019 and March 31, 2022 as second-line to fourth-line treatment in patients with advanced LSqCC who had been pretreated with ICIs...
December 2023: JTO clinical and research reports
https://read.qxmd.com/read/37337501/gemcitabine-induced-radiation-recall-phenomenon-in-cervical-cancer-a-case-report
#3
Jesus Paula Carvalho, Daniela Freitas, Samir Hanna, Isabela A Velho, Filomena M Carvalho
The radiation recall phenomenon is a rare, massive inflammatory reaction induced by some chemotherapeutic agents in previously irradiated areas. When it occurs in the pelvis it looks like a recurrence. Recognizing this phenomenon is paramount to avoiding unnecessary surgical intervention and complications. Symptoms manifest as dermatitis, mucositis, myositis, esophagitis, colitis, proctitis, and pneumonitis in areas within the irradiation field. Most patients respond to clinical treatment with corticosteroids...
May 2023: Curēus
https://read.qxmd.com/read/37287014/re-evaluating-the-risk-factors-for-radiation-pneumonitis-in-the-era-of-immunotherapy
#4
REVIEW
Feihu Chen, Jiling Niu, Min Wang, Hui Zhu, Zhijun Guo
As one of the common complications of radiotherapy, radiation pneumonia (RP) limits the prognosis of patients. Therefore, better identifying the high-risk factors that lead to RP is essential to effectively prevent its occurrence. However, as lung cancer treatment modalities are being replaced and the era of immunotherapy has arrived, literature that reviews the parameters and mode of radiotherapy, chemotherapy drugs, targeted drugs and current hot immune checkpoint inhibitors related to RP is lacking. This paper summarizes the risk factors for radiation pneumonia by retrieving and analysing previously published literature and the results of large clinical trials...
June 7, 2023: Journal of Translational Medicine
https://read.qxmd.com/read/36535566/pembrolizumab-monotherapy-versus-chemotherapy-in-platinum-pretreated-recurrent-or-metastatic-nasopharyngeal-cancer-keynote-122-an-open-label-randomized-phase-iii-trial
#5
RANDOMIZED CONTROLLED TRIAL
A T C Chan, V H F Lee, R-L Hong, M-J Ahn, W Q Chong, S-B Kim, G F Ho, P B Caguioa, N Ngamphaiboon, C Ho, M A S A Aziz, Q S Ng, C-J Yen, N Soparattanapaisarn, R K-C Ngan, S K Kho, M L A Tiambeng, T Yun, V Sriuranpong, A P Algazi, A Cheng, E Massarelli, R F Swaby, S Saraf, J Yuan, L L Siu
BACKGROUND: Pembrolizumab previously demonstrated robust antitumor activity and manageable safety in a phase Ib study of patients with heavily pretreated, programmed death ligand 1 (PD-L1)-positive, recurrent or metastatic nasopharyngeal carcinoma (NPC). The phase III KEYNOTE-122 study was conducted to further evaluate pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent and/or metastatic NPC. Final analysis results are presented. PATIENTS AND METHODS: KEYNOTE-122 was an open-label, randomized study conducted at 29 sites, globally...
March 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/35851350/-a-case-of-drug-induced-pneumomediastinum-preceding-interstitial-pneumonitis-onset-during-treatment-with-a-first-line-regimen-of-gnp-in-a-patient-with-unresectable-pancreatic-cancer
#6
JOURNAL ARTICLE
Kanji Minamoto, Toshio Ikeda, Kayoko Araki, Miki Hamada
BACKGROUND: The highest prevalence of drug-induced interstitial pneumonitis(IP)occurs in patients receiving antineoplastic agents, such as cytotoxic chemotherapeutic drugs, molecular targeted drugs, and immune checkpoint inhibitors. A certain period of the treatment for IP requires discontinuation of the anticancer therapy, resulting in progression of the malignant status. CASE: A 70-year-old man was incidentally diagnosed with locally advanced unresectable pancreatic cancer in the course of his treatment for ventricular dysrhythmia...
July 2022: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/35804997/durvalumab-after-sequential-high-dose-chemoradiotherapy-versus-standard-of-care-soc-for-stage-iii-nsclc-a-bi-centric-trospective-comparison-focusing-on-pulmonary-toxicity
#7
JOURNAL ARTICLE
Romana Wass, Maximilian Hochmair, Bernhard Kaiser, Brane Grambozov, Petra Feurstein, Gertraud Weiß, Raphaela Moosbrugger, Felix Sedlmayer, Bernd Lamprecht, Michael Studnicka, Franz Zehentmayr
INTRODUCTION: The standard of care (SoC) for unresectable stage III non-small-cell lung cancer (NSCLC) is durvalumab maintenance therapy after concurrent chemoradiation in patients with PD-L1 > 1%. However, the concurrent approach is only amenable for about one-third of patients due to co-morbidities. Although sequential regimens are usually not regarded as curative, these schedules applied in a dose-escalated manner may be similarly radical as SoC. As combining high-dose radiation and durvalumab remains a question of debate this retrospective bi-center study aims to evaluate pulmonary toxicity after high-dose chemoradiotherapy beyond 70 Gy compared to SoC...
June 30, 2022: Cancers
https://read.qxmd.com/read/35528774/interstitial-lung-disease-associated-with-agaricus-blazei-murill-in-a-patient-with-pancreatic-ductal-adenocarcinoma-receiving-gemcitabine-based-therapy
#8
Naoto Iwai, Takashi Okuda, Ryo Sawada, Tomoya Ohara, Chie Hattori, Masashi Taniguchi, Hiroaki Sakai, Kohei Oka, Tasuku Hara, Toshifumi Tsuji, Toshiyuki Komaki, Junichi Sakagami, Keizo Kagawa, Osamu Dohi, Hiroaki Yasuda, Yoshito Itoh
A male in his sixties with locally advanced pancreatic ductal adenocarcinoma (PDAC) was administered gemcitabine plus nab-paclitaxel therapy. Computed tomography (CT) scans after five courses revealed nonspecific interstitial pneumonitis in addition to PDAC aggravation. No evidence of respiratory infection was detected, and his condition was stable and asymptomatic at diagnosis. Sputum test and interferon-gamma release assay revealed no evidence of tuberculosis. Through careful history taking, the patient was found to be taking dietary supplementation with Agaricus blazei Murill extract for approximately 1 month...
January 2022: Case Reports in Gastroenterology
https://read.qxmd.com/read/35393247/phase-ii-trial-of-combination-nab-paclitaxel-and-gemcitabine-in-non-squamous-non-small-cell-lung-cancer-after-progression-on-platinum-and-pemetrexed
#9
JOURNAL ARTICLE
Christine A Ciunci, Jacob B Reibel, Tracey L Evans, Rosemarie Mick, Joshua M Bauml, Charu Aggarwal, Melina E Marmarelis, Aditi P Singh, Christopher D'Avella, Roger B Cohen, Corey J Langer
BACKGROUND: Better therapies are needed to improve survival in metastatic non-small cell lung cancer (NSCLC). Given the synergy of combination nab-paclitaxel and gemcitabine in metastatic pancreatic cancer and their individual activity in advanced NSCLC, we sought to determine whether the same combination would confer a therapeutic benefit in the second-line therapy of recurrent or metastatic non-squamous (NSQ) NSCLC. MATERIALS AND METHODS: This single-arm phase II trial of nab-paclitaxel and gemcitabine was performed from June 2015 to April 2020 at an academic referral cancer center...
June 2022: Clinical Lung Cancer
https://read.qxmd.com/read/35008384/arterial-administration-of-dna-crosslinking-agents-with-restraint-of-homologous-recombination-repair-by-intravenous-low-dose-gemcitabine-is-effective-for-locally-advanced-pancreatic-cancer
#10
JOURNAL ARTICLE
Hiromu Mori, Shuichi Tanoue, Ryo Takaji, Shinya Ueda, Mika Okahara, Saori Sugi Ueda
(1) Background: Pretreatment by Rad51-inhibitory substances such as gemcitabine followed by arterial chemotherapy using antineoplastic agents causing DNA crosslink might be more beneficial for patients with locally advanced pancreatic cancers than conventional treatments. The efficacy of arterial administration of DNA crosslinking agents with pretreatment of intravenous low-dose gemcitabine for patients with unresectable locally advanced or metastatic pancreatic cancer (LAPC or MPC) is evaluated. (2) Methods: A single-arm, single-center, institutional review board-approved prospective study was conducted between 2005 and 2015...
January 3, 2022: Cancers
https://read.qxmd.com/read/34618912/combination-of-pd-1-inhibitor-with-gvd-gemcitabine-vinorelbine-liposomal-doxorubicin-versus-gvd-regimen-as-second-line-therapy-for-relapsed-refractory-classical-hodgkin-lymphoma
#11
JOURNAL ARTICLE
Yu-Chen Zhang, Jin-Ni Wang, Shu-Yun Ma, Jun Cai, Ning Su, Hui-Qiang Huang, Zhi-Ming Li, Zhong-Jun Xia, He Huang, Pan-Pan Liu, Yi Xia, Qing-Qing Cai
Patients with classical Hodgkin lymphoma (cHL) who do not achieve complete remission (CR) after second-line chemotherapy have poor clinical outcomes. Besides, conventional salvage chemotherapy regimens have an unsatisfactory CR rate. The present retrospective study reports the efficacy and toxicity of the GVD (gemcitabine, vinorelbine, liposomal doxorubicin) regimen with or without programmed cell death 1 (PD-1) inhibitor for patients with cHL who failed first-line treatment. A total of 103 patients with cHL (GVD+PD-1 group, n = 27; GVD group, n = 76) with response assessment based on positron emission tomography were included...
January 2022: British Journal of Haematology
https://read.qxmd.com/read/33849579/risk-factors-for-radiation-pneumonitis-in-lung-cancer-patients-with-subclinical-interstitial-lung-disease-after-thoracic-radiation-therapy
#12
JOURNAL ARTICLE
Fangjuan Li, Hui Liu, Hongyu Wu, Shixiong Liang, Yaping Xu
BACKGROUND: Previous studies have found that patients with subclinical interstitial lung disease (ILD) are highly susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy. In the present study we aimed to evaluate the incidence of and risk factors for RP after thoracic intensity-modulated radiation therapy in lung cancer patients with subclinical ILD. METHODS: We retrospectively analyzed data from lung cancer patients with subclinical ILD who were treated with thoracic intensity-modulated radiation therapy with a prescribed dose of ≥ 50 Gy in our institution between January 2016 and December 2017...
April 13, 2021: Radiation Oncology
https://read.qxmd.com/read/33194133/gemcitabine-induced-pneumonitis-a-case-report-and-review-of-literature
#13
Nishanth Thalambedu, Abdallah H El-Habr
We are reporting a case of pneumonitis in an 81 year old-aged woman due to gemcitabine who was successfully managed with steroids. We also reviewed the literature and found previous case reports of gemcitabine induced pneumonitis.We reported this case to alert physicians to be aware of this infrequent and sometimes fatal complication from gemcitabine.
October 29, 2020: Journal of Community Hospital Internal Medicine Perspectives
https://read.qxmd.com/read/33083430/intravesically-instilled-gemcitabine-induced-lung-injury-in-a-patient-with-invasive-urothelial-carcinoma-a-case-report
#14
Xiao-Ming Zhou, Cen Wu, Xiu Gu
BACKGROUND: Gemcitabine is a chemotherapy agent with relatively low toxicities, as a valid option for elderly patients with underlying diseases. Gemcitabine-induced pulmonary toxicities are rare and various, ranging from self-limited episodes of bronchospasm to fatal, progressive, severe, interstitial pneumonitis and respiratory failure. Intravesical gemcitabine instillations are commonly used to reduce recurrence or progression for non-muscle-invasive bladder cancer or urothelial cancer...
October 6, 2020: World Journal of Clinical Cases
https://read.qxmd.com/read/32971005/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in-previously-untreated-patients-with-unresectable-locally-advanced-or-metastatic-urothelial-carcinoma-danube-a-randomised-open-label-multicentre-phase-3-trial
#15
RANDOMIZED CONTROLLED TRIAL
Thomas Powles, Michiel S van der Heijden, Daniel Castellano, Matthew D Galsky, Yohann Loriot, Daniel P Petrylak, Osamu Ogawa, Se Hoon Park, Jae-Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J Eigl, Howard Gurney, Som D Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P Fay, Ignacio Duran, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok K Gupta, Wendy Levin, Joaquim Bellmunt
BACKGROUND: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma. METHODS: DANUBE is an open-label, randomised, controlled, phase 3 trial in patients with untreated, unresectable, locally advanced or metastatic urothelial carcinoma, conducted at 224 academic research centres, hospitals, and oncology clinics in 23 countries...
December 2020: Lancet Oncology
https://read.qxmd.com/read/32553118/berzosertib-plus-gemcitabine-versus-gemcitabine-alone-in-platinum-resistant-high-grade-serous-ovarian-cancer-a-multicentre-open-label-randomised-phase-2-trial
#16
RANDOMIZED CONTROLLED TRIAL
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, Richard T Penson, Susan T Schumer, L Austin Doyle, Elizabeth K Lee, Elise C Kohn, Linda R Duska, Marta A Crispens, Alexander B Olawaiye, Ira S Winer, Lisa M Barroilhet, Siqing Fu, Michael T McHale, Russell J Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne S Quinn, Brittany Bowes, Alan D D'Andrea, Geoffrey I Shapiro, Ursula A Matulonis
BACKGROUND: High-grade serous ovarian cancers show increased replication stress, rendering cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (through deleterious TP53 mutations), premature S phase entry (due to CCNE1 amplification, RB1 loss, or CDKN2A mRNA downregulation), alterations of homologous recombination repair genes, and expression of oncogenic drivers (through MYC amplification and other mechanisms). We hypothesised that the combination of the selective ATR inhibitor, berzosertib, and gemcitabine could show acceptable toxicity and superior efficacy to gemcitabine alone in high-grade serous ovarian cancer...
July 2020: Lancet Oncology
https://read.qxmd.com/read/32516143/interstitial-pneumonitis-a-newly-recognized-consequence-of-intravesical-gemcitabine-therapy
#17
JOURNAL ARTICLE
Venkata Satish Pendela, Bassil Said, Pujitha Kudaravalli, Mamta Chhabria, Dharmini Manogna, Michael Gurell
No abstract text is available yet for this article.
June 2, 2020: American Journal of Therapeutics
https://read.qxmd.com/read/32381982/-a-case-of-pulmonary-metastasis-from-hilar-cholangiocarcinoma-treated-by-stereotactic-body-radiotherapy
#18
JOURNAL ARTICLE
Hiroyuki Ishida, Yasuji Seyama, Yusuke Ome, Masaru Matsumura, Satoshi Nemoto, Manami Doi, Jun Muto, Sara Hayakawa, Katsuyuki Karasawa, Hirotoshi Horio, Shinichiro Horiguchi, Goro Honda
We report a case of pulmonary metastasis from hilar cholangiocarcinoma successfully treated by stereotactic body radiotherapy. The patient was a 70-year-old woman who underwent extended left hemi-hepatectomy with bile duct reconstruction for hilar cholangiocarcinoma at the age of 67. Pathological diagnosis indicated a well-differentiated adenocarcinoma. We followed up the patient without adjuvant chemotherapy. Nineteen months after the initial resection, a solitary pulmonary metastasis was detected in the right upper lobe...
February 2020: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/32169783/a-phase-ib-study-of-durvalumab-with-or-without-tremelimumab-and-platinum-doublet-chemotherapy-in-advanced-solid-tumours-canadian-cancer-trials-group-study-ind226
#19
MULTICENTER STUDY
Rosalyn A Juergens, Desiree Hao, Peter M Ellis, Dongsheng Tu, Mihaela Mates, Christian Kollmannsberger, Penelope A Bradbury, Moustapha Tehfe, Paul Wheatley-Price, Andrew Robinson, Gwyn Bebb, Janessa Laskin, John Goffin, John Hilton, Anna Tomiak, Sebastien Hotte, Glenwood D Goss, Pamela Brown-Walker, Xiaoqun Sun, Ming-Sound Tsao, Michael Cabanero, Isabelle Gauthier, Xuyang Song, Phillip A Dennis, Lesley K Seymour, Martin Smoragiewicz, Scott A Laurie
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into one of six dose levels (DL) of Du ± Tr which included concomitant treatment with standard platinum-doublet regimens; (pemetrexed, gemcitabine, etoposide, (each with cisplatin or carboplatin) or nab-paclitaxel (with carboplatin)). Dose escalation was according to a Rolling Six type design. Both weight-based and fixed dosing of Du and Tr were explored...
May 2020: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31842910/risk-factors-of-grade-%C3%A2-2-radiation-pneumonitis-after-gemcitabine-induction-chemotherapy-for-patients-with-non-small-cell-lung-cancer
#20
JOURNAL ARTICLE
Liming Sheng, Xiaoying Cui, Lei Cheng, Ying Chen, Xianghui Du
OBJECTIVES: To observe the risk factors affecting the occurrence of RP after gemcitabine-based induction chemotherapy. METHODS: Between January 2010 and December 2017, patients with NSCLC received gemcitabine or docetaxel chemotherapy, followed by radiotherapy at Zhejiang cancer hospital were enrolled in this study. Patients were treated with gemcitabine or docetaxel induction chemotherapy, followed by radiotherapy or concurrent chemoradiotherapy. Acute radiation pneumonitis was scored post chemoradiotherapy...
December 16, 2019: Radiation Oncology
keyword
keyword
103367
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.